Work

Impact of stress exposure and pharmacological intervention on a mouse model of Alzheimer’s disease

Year: 2012
Type: dissertation
Abstract: In this dissertation, we have made use of the APPswe/PS1ΔE9 mouse model of AD, created by Dr. David Borchelt and coworkers [47].This mouse model carries a double genetic mutation: the Swedish mutation on the APP695 isoform (K694L/N595L), which was first discovered in a Swedish family, combined with the PS1 mutation which leads to a deletion of exon 9 within that gene.Both mutations are under the expression of the mouse prion protein promotor, thereby directing expression of both transgenes mainly to CNS neurons [48].The human/mouse chimeric APP695 Swedish mutation leads to a 2-3 fold overexpression of the APP protein [48], while the PS1ΔE9 mutation causes an increase in the production of Aβ42 over Aβ40 [49], thereby leading to plaque deposition from 4 months of age [50].The first cognitive deficits are reported from 7 months of age onwards [51,52].The recapitulation of amyloid pathology and cognitive deficits as seen in AD patients, and the relative quick onset of pathology and symptoms, makes the APPswe/PS1ΔE9 mouse model a suitable model for investigating AD-related processes. Current treatment optionsAD is an incurable illness, and its treatment options are limited.Today, the only types of medication approved for the treatment of AD are acetylcholinesterase inhibitors, e.g.rivastigmine and donepezil, and one NMDA-receptor antagonist, i.e. memantine [53].
Language: English
Open Access status: green
OpenAlex ID: W814693468
Cites: 717
Cited by:
Related to: 9